Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
12.56
+0.71 (5.99%)
Mar 4, 2026, 2:32 PM EST - Market open

Entrada Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
90.39101.2167.645.16291.06
Short-Term Investments
205.3318.79284.37143.56-
Cash & Short-Term Investments
295.7420351.97188.71291.06
Cash Growth
-29.59%19.33%86.51%-35.16%645.46%
Accounts Receivable
1.183.685.88--
Other Current Assets
9.3816.3611.9221.167.64
Total Current Assets
306.25440.04369.77209.88298.7
Net Property, Plant & Equipment
67.7682.0592.6833.026.26
Other Long-Term Assets
3.364.236.749.160.87
Total Assets
377.38526.32469.19252.06305.83
Accounts Payable
2.294.263.285.990.71
Accrued Expenses
17.6813.3411.337.586.01
Current Portion of Leases
4.147.567.918.41-
Unearned Revenue
0.3413.65132.26--
Other Current Liabilities
-0.674.02--
Total Current Liabilities
24.4539.48158.821.976.72
Long-Term Leases
46.7951.6560.3217.53-
Other Long-Term Liabilities
-6.517.72-0.4
Total Long-Term Liabilities
46.7958.1668.0417.530.4
Total Liabilities
71.2597.64226.8339.57.12
Common Stock
00000
Additional Paid-in Capital
578.57558.06437.13402.89392.38
Accumulated Other Comprehensive Income
0.65-0.040.2-2.06-
Retained Earnings
-273.09-129.34-194.97-188.29-93.67
Total Common Shareholders' Equity
306.13428.68242.36212.55298.72
Shareholders' Equity
306.13428.68242.36212.55298.72
Total Liabilities & Equity
377.38526.32469.19252.06305.83
Total Debt
50.9359.2168.2325.940
Net Cash (Debt)
244.77360.79283.74162.78291.06
Net Cash Growth
-32.16%27.16%74.31%-44.08%645.46%
Net Cash Per Share
5.929.258.595.2046.44
Book Value
306.13428.68242.36212.55298.72
Book Value Per Share
7.4010.997.336.7947.66
Tangible Book Value
306.13428.68242.36212.55298.72
Tangible Book Value Per Share
7.4010.997.336.7947.66
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q